Products Obinutuzumab is commercially available as a concentrate for the preparation of an infusion solution (Gazyvaro). It has been approved in many countries since 2014. Structure and properties Obinutuzumab is a recombinant, monoclonal, and humanized type II antibody against CD20 of the IgG1 isotype. It has a molecular weight of approximately 150 kDa. Obinutuzumab is … Obinutuzumab
Products Ocrelizumab was approved in many countries and in the United States in 2017 and in the EU in 2018 as an infusion concentrate (Ocrevus). Structure and properties Ocrelizumab is a humanized IgG1 monoclonal antibody with a molecular mass of 145 kDa. It is produced by biotechnological methods. Ocrelizumab is the successor agent to rituximab … Ocrelizumab
Products Benralizumab was approved as a solution for injection in the United States in 2017 and in the EU and many countries in 2018 (Fasenra). Structure and properties Benralizumab is a humanized and afucosylated IgG1κ antibody with a molecular mass of 150 kDa. It is produced by biotechnological methods. Omission of the fucose in the … Benralizumab
Products Satralizumab was approved in many countries in 2020 as a solution for injection (Enspryng). Structure and properties Satralizumab is a humanized IgG2 monoclonal antibody produced by biotechnological methods. Effects Satralizumab (ATC L04AC19) has anti-inflammatory and immunosuppressive properties. The effects are due to binding to the soluble and membrane-bound human IL-6 receptor (IL-6R), preventing signal … Satralizumab
Products Ofatumumab was approved in 2009 as a concentrate for the preparation of an infusion solution for leukemia treatment (Arzerra). In 2020, a solution for injection was approved in the United States for MS treatment (Kesimpta). Structure and properties Ofatumumab is a human IgG1 monoclonal antibody produced by biotechnological methods. It has a molecular mass … Ofatumumab
1. symptom treatment Beta2-sympathomimetics are derived from epinephrine. They selectively stimulate the adrenergic β2-receptors of bronchial muscles and thus have a bronchospasmolytic effect. For rapid symptom relief, fast-acting agents are usually administered by inhalation, for example, with a metered-dose inhaler or a powder inhaler. They should be used only when needed. An increase in administration … Antiasthmatics
Products Golimumab is commercially available as a solution for injection (Simponi). It was approved in many countries in 2010. Structure and properties Golimumab (Mr = 150 kDa) is a human IgG1κ-monoclonal antibody. Effects Golimumab (ATC L04AB06) has selective immunosuppressive and anti-inflammatory properties. The effects are based on binding to the soluble and membrane-bound proinflammatory cytokine … Golimumab
Products Olaratumab was approved in the United States and EU in 2016 and in many countries in 2017 as a concentrate for the preparation of an infusion solution (Lartruvo). Structure and properties Olaratumab is a human IgG1 monoclonal antibody that binds to PDGFRα. It is produced by biotechnological methods and has a molecular weight of … Olaratumab
Products Eculizumab is commercially available as a concentrate for the preparation of an infusion solution (Soliris). It was approved in many countries in January 2010. Structure and Properties Eculizumab is a monoclonal antibody produced by recombinant DNA technology in NSO cell lines. It is composed of two heavy and two light chains of amino acids … Eculizumab
Products Lokivetmab was approved in the EU in 2017 and in many countries in 2018 in the form of a solution for injection (Cytopoint, Zoetis Belgium SA). Lokivetmab was the first monoclonal antibody to be cleared for animals. In the United States, locivetmab was approved in 2015 (Canine Atopic Dermatitis Immunotherapeutic). Structure and properties Lokivetmab … Lokivetmab
Products Elotuzumab was approved in the United States in 2015 and in the EU and Switzerland in 2016 as a powder for the preparation of an infusion solution (Empliciti). Structure and properties Elotuzumab is a humanized IgG1 monoclonal antibody with a molecular weight of 148.1 kDa. It is produced by biotechnological methods. Effects Elotuzumab (ATC … Elotuzumab
Products Daratumumab was approved as an infusion product in the United States in 2015 and in many countries and the EU in 2016 (Darzalex). Structure and properties Daratumumab is a humanized IgG1κ monoclonal antibody with a molecular mass of approximately 148 kDa. It is produced by biotechnological methods. Effects Daratumumab (ATC L01XC24) has antitumor and … Daratumumab
